ICOTYDE psoriatic arthritis catalyst: pivotal data expected later in 2026, supporting potential expansion beyond plaque psoriasis.
INLEXZO bladder-cancer expansion: papillary, BCG-experienced and frontline programs are expected to broaden use beyond the initial CIS population.
Two 2026 surgical-robotics launches: OTTAVA and MONARCH for urology, pending regulatory authorization.
Raised full-year 2026 operational sales guidance to 6.5%-7.1%, citing new-launch uptake and expected second-half improvement.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Johnson & Johnson and 4,900+ companies.